The BCL2 inhibitor venetoclax is approved in the United States for only a subset of patients with refractory chronic lymphocytic leukemia. However, in light of data presented at the American Society of Hematology 2017 Annual Meeting, clinicians are thinking ahead to administering the drug more broadly—in combinations and as a first-line therapy—for other patients with the disease.

中文翻译：

---

Venetoclax数据提示对CLL治疗的反思

BCL2抑制剂Venetoclax在美国仅获批准用于部分难治性慢性淋巴细胞性白血病患者。但是，根据在美国血液学学会2017年年会上提交的数据，临床医生正在考虑向其他合并有疾病的患者更广泛地联合或作为一线治疗药物。